CERS Insider Trading

Insider Ownership Percentage: 3.40%
Insider Buying (Last 12 Months): $9,675.00
Insider Selling (Last 12 Months): $816,701.40

Cerus Insider Trading History Chart

This chart shows the insider buying and selling history at Cerus by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$665ksoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$2M$0$2MTotal Insider BuyingTotal Insider Selling

Cerus Share Price & Price History

Current Price: $1.43
Price Change: Price Decrease of -0.06 (-4.03%)
As of 03/26/2025 05:00 PM ET

This chart shows the closing price history over time for CERS up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMar$1.43Closing price on 03/26/25:

SEC Filings (Institutional Ownership Changes) for Cerus (NASDAQ:CERS)

78.37% of Cerus stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at CERS by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$12Mbought$18MsoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$10M$0$10MTotal InflowsTotal Outflows
Cerus logo
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.
Read More on Cerus

Today's Range

Now: $1.43
Low: $1.40
High: $1.48

50 Day Range

MA: $1.70
Low: $1.39
High: $2.15

52 Week Range

Now: $1.43
Low: $1.38
High: $2.54

Volume

1,270,175 shs

Average Volume

1,221,488 shs

Market Capitalization

$265.68 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.56

Who are the company insiders with the largest holdings of Cerus?

Cerus' top insider investors include:
  1. William Mariner Greenman (CEO)
  2. Vivek K Jayaraman (COO)
  3. Kevin Dennis Green (CFO)
  4. Richard J Benjamin (Insider)
  5. Chrystal Jensen (Insider)
  6. Carol Moore (SVP)
  7. Eric Bjerkholt (Director)
  8. Daniel N Swisher Jr (Director)
  9. Ann Lucena (Director)
  10. Hua Shan (Director)
Learn More about top insider investors at Cerus.

Who are the major institutional investors of Cerus?

Cerus' top institutional investors include:
  1. ARK Investment Management LLC — 11.21%
  2. Vanguard Group Inc. — 5.61%
  3. Wasatch Advisors LP — 4.48%
  4. Sumitomo Mitsui Trust Group Inc. — 3.48%
  5. Nikko Asset Management Americas Inc. — 3.48%
  6. Senvest Management LLC — 3.44%
Learn More about top institutional investors of Cerus stock.

Which major investors are selling Cerus stock?

Within the last quarter, CERS stock was sold by these institutional investors:
  1. Primecap Management Co. CA
  2. Bank of America Corp DE
  3. Sumitomo Mitsui Trust Group Inc.
  4. Nikko Asset Management Americas Inc.
  5. Sepio Capital LP
  6. Vanguard Group Inc.
  7. Voya Investment Management LLC
  8. D. E. Shaw & Co. Inc.
Within the previous year, company insiders that have sold Cerus company stock include:
  1. William Mariner Greenman (CEO)
  2. Vivek K Jayaraman (COO)
  3. Kevin Dennis Green (CFO)
  4. Richard J Benjamin (Insider)
  5. Chrystal Jensen (Insider)
Learn More investors selling Cerus stock.

Which major investors are buying Cerus stock?

During the previous quarter, CERS stock was bought by institutional investors including:
  1. ARK Investment Management LLC
  2. Wasatch Advisors LP
  3. Millennium Management LLC
  4. Squarepoint Ops LLC
  5. Senvest Management LLC
  6. Two Sigma Investments LP
  7. Raymond James Financial Inc.
  8. Raymond James Financial Inc.
Within the last year, these company insiders have bought Cerus stock:
  1. William Mariner Greenman (CEO)
  2. Vivek K Jayaraman (COO)
  3. Kevin Dennis Green (CFO)
  4. Richard J Benjamin (Insider)
Learn More investors buying Cerus stock.